XENE
Xenon Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$35.08
+4.75%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- -31.9%
- EBIT
- -38.8%
- EPS
- -33.5%
- Free cash flow
- -46.2%
- Operating cash flow
- -46.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- -15.1%
- EPS
- -2.4%
Three-year CAGR
- Revenue
- -7.4%
- EBITDA
- -45.2%
- EBIT
- -33.6%
- Net income
- -47.6%
- EPS
- -44.9%
- Free cash flow
- -51.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026